Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability:

		Three Months Ended September 30,
	Fair Value Hierarchy Level	2022		2021
Fair value as of June 30, 2022 and 2021, respectively	3	$	—	$	11,607
Non-cash research and development expense		—		5,702
Cash receipts from SFJ		—		750
Change in the fair value of development derivative liability		—		3,328
Fair value at end of period	3	$	—	$	21,387

		Nine Months Ended September 30,
	Fair Value Hierarchy Level	2022		2021
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively	3	$	27,726	$	—
Non-cash research and development expense		4,951		11,497
Cash receipts from SFJ		750		2,250
Change in the fair value of development derivative liability		(33,427)		7,640
Fair value at end of period	3	$	—	$	21,387